Proteas Bioanalytics Inc.

From a single drop of blood, Proteas Bioanalytics is able to detect the presence of human diseases at their earliest stage, before the onset of symptoms. Our technologies will also provide objective guidance to implement effective treatment options. Proteas Bioanalytics has also developed advanced technologies for the in-depth analysis and biological understanding of single cells and tissue biopsy specimens that complement and validates our blood-based analysis platform. The field of blood and single-cell proteomics offers a tremendous opportunity to reshape the diagnosis and treatment of almost all diseases. Currently used proteomics technologies do not meet the stringent FDA performance criteria due to the high complexity and heterogeneity of human blood, tissue and cells and their analysis method. The Proteas Bioanalytics proprietary proteomics technology: ▪ includes the analysis of all proteins expressed in blood, cells and tissues during healthy or diseased situations ▪ leverages 30-years of our published methods and overcomes previous limitations ▪ leads to the development of novel protein-based biological signatures with actionable clinical importance ▪ leads to the development of novel proteins markers for monitoring the response to treatment (pharmacology, immunotherapy, nutritional intervention, lifestyle intervention) ➢ We are both a platform and disease-specific biosignature with assay development company ➢ Our core proteomics technology can be partnered across indications to pharma and biotech companies, while our internal biomarker platforms will be developed for high unmet needs in the clinical arena The Proteas Bioanalytics team has extensive industrial, academic, and government experience in research and development, partnering, biology, pharmacology, analytical chemistry, nanotechnology, mathematics and artificial intelligence that will promotes the development of a state-of-the-art and innovative platforms.

Syntr Health Technologies, Inc.

Late Clinical Stage company using our FDA Cleared system for a variety of surgical indications like breast cancer reconstruction, facial aesthetics, wound care, and orthopedic surgery.

Stemson Therapeutics

At Stemson Therapeutics, we envision a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair.

Adjuvia Therapeutics

Mitochondrial dysfunction lies at the core of many chronic and rare diseases. It leads to excessive oxidative stress, chronic inflammation, tissue damage, and ultimately, organ failure. Adjuvia is developing novel oral therapeutics to address mitochondrial dysfunction, reverse chronic degenerative diseases, and promote longevity. Adjuvia’s lead program, ATI-105, is a proprietary nanoparticle formulation of the powerful small molecule antioxidant astaxanthin, with unprecedented multi-organ uptake and a unique molecular structure that spans across cell and mitochondrial membranes to neutralize oxidative stress and promote efficient ATP energy production. More than just an antioxidant, ATI-105 contains a proprietary molecular configuration of astaxanthin that potently engages in cell signaling pathways that inhibit chronic inflammation, promote cellular regeneration, reverse organ fibrosis, and prolong lifespan. ATI-105 is currently in IND-enabling studies to treat rare inherited mitochondrial diseases such as Friedreich’s Ataxia (FA), with clinical trials to be performed at the Children’s Hospital of Philadelphia (CHOP) and UCLA. Additional Ph2 trials are planned for IVF/fertility and cardiometabolic disease/MASH. Adjuvia is well positioned to achieve commercial success, with wholly-owned issued and pending IP, a clear path to fast-track FDA approval, and a seasoned team of biotech entrepreneurs and drug developers.

Teiko.bio

Teiko.bio equips scientific and clinical teams with actionable intelligence at a cellular level. Pairing cutting-edge mass cytometry with a high-dimensional machine learning model, teiko.bio unlocks more information about individual immune characteristics to drive clinical insights.